title: Streptococcus thermophilus fermented milk reduces serum MDA-LDL and blood pressure in healthy and mildly hypercholesterolaemic adults.
abstract: Low-density lipoprotein (LDL)-cholesterol, malondialdehyde-modified low-density lipoprotein (MDA-LDL), MDA-LDL/LDL-cholesterol in serum, and blood pressure are considered useful risk markers of cardiovascular diseases. This study aimed to examine whether a fermented milk containing Streptococcus thermophilus YIT 2001 (ST), which has high anti-oxidative activity, would benefit healthy and mildly hyper-LDL-cholesterolaemic adults via a randomised, double-blind, placebo-controlled trial. ST-fermented milk or non-fermented placebo milk (PC) was consumed once a day for 12 weeks by 29 and 30 subjects, respectively, with average serum LDL-cholesterol levels of about 140 mg/dl. Serum levels of LDL-cholesterol and MDA-LDL and blood pressure were analysed before (baseline) and after consumption. Comparisons of the responses between both groups were assessed using analysis of covariance (ANCOVA, with the baseline value as the covariate). ANCOVA demonstrated that the ST group had significant reductions in MDA-LDL, MDA-LDL/LDL-cholesterol, systolic blood pressure (SBP), and diastolic blood pressure (DBP) compared with the PC group during the consumption period (P<0.05). Moreover, stratified analysis revealed that there were significant reductions in MDA-LDL, MDA-LDL/LDL-cholesterol, SBP, and DBP in the ST group compared with the PC group during the consumption period in subjects who had above median (65 U/l) levels of oxidative stress marker MDA-LDL at baseline (P<0.05), but not in subjects with levels below the median. These findings suggest that daily consumption of ST-fermented milk may be beneficial in healthy or mildly hyper-LDL cholesterolaemic subjects through reductions in risk marker values of oxidative stress and/or cardiovascular diseases. The benefits were particularly remarkable in subjects who had higher levels of MDA-LDL.
authors.affiliation: 1 Yakult Central Institute, 5-11 Izumi, Kunitachi-shi, Tokyo, 186-8650 Japan.
authors.forename: M
authors.initials: M
authors.lastname: Ito
authors.affiliation: 1 Yakult Central Institute, 5-11 Izumi, Kunitachi-shi, Tokyo, 186-8650 Japan.
authors.forename: S
authors.initials: S
authors.lastname: Kusuhara
authors.affiliation: 1 Yakult Central Institute, 5-11 Izumi, Kunitachi-shi, Tokyo, 186-8650 Japan.
authors.forename: W
authors.initials: W
authors.lastname: Yokoi
authors.affiliation: 1 Yakult Central Institute, 5-11 Izumi, Kunitachi-shi, Tokyo, 186-8650 Japan.
authors.forename: T
authors.initials: T
authors.lastname: Sato
authors.affiliation: 2 2Development Department, Yakult Honsha Co., Ltd., 1-1-19 Higashi-shinbashi, Minato-ku, Tokyo, 105-8660 Japan.
authors.forename: H
authors.initials: H
authors.lastname: Ishiki
authors.affiliation: 2 2Development Department, Yakult Honsha Co., Ltd., 1-1-19 Higashi-shinbashi, Minato-ku, Tokyo, 105-8660 Japan.
authors.forename: S
authors.initials: S
authors.lastname: Miida
authors.affiliation: 2 2Development Department, Yakult Honsha Co., Ltd., 1-1-19 Higashi-shinbashi, Minato-ku, Tokyo, 105-8660 Japan.
authors.forename: A
authors.initials: A
authors.lastname: Matsui
authors.affiliation: 2 2Development Department, Yakult Honsha Co., Ltd., 1-1-19 Higashi-shinbashi, Minato-ku, Tokyo, 105-8660 Japan.
authors.forename: K
authors.initials: K
authors.lastname: Nakamori
authors.affiliation: 2 2Development Department, Yakult Honsha Co., Ltd., 1-1-19 Higashi-shinbashi, Minato-ku, Tokyo, 105-8660 Japan.
authors.forename: C
authors.initials: C
authors.lastname: Nonaka
authors.affiliation: 1 Yakult Central Institute, 5-11 Izumi, Kunitachi-shi, Tokyo, 186-8650 Japan.
authors.forename: K
authors.initials: K
authors.lastname: Miyazaki
mesh_terms: D000328:Adult; D000975:Antioxidants / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000628:therapy; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000502:physiology*; D002318:Cardiovascular Diseases / Q000628:therapy; D008078:Cholesterol, LDL / Q000097:blood*; D043302:Cultured Milk Products / Q000382:microbiology*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D008315:Malondialdehyde / Q000031:analogs & derivatives* / Q000097:blood; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects; D019936:Probiotics / Q000627:therapeutic use*; D048249:Streptococcus thermophilus; D055815:Young Adult
chemical_list: D000975:Antioxidants; D015415:Biomarkers; D008078:Cholesterol, LDL; D008077:Lipoproteins, LDL; C569869:malondialdehyde-low density lipoprotein, human; D008315:Malondialdehyde
keywords: anti-oxidative activity; atherosclerosis; cardiovascular diseases; lactic acid bacteria; oxidative stress